12:00 AM
Jan 23, 2012
 |  BC Week In Review  |  Company News  |  Deals

Immunovative Therapies, Novo Energies deal

In December, Immunovative granted Novo Energies an exclusive, worldwide license to commercialize all products covered under Immunovative's patents or patent applications. Immunovative, which has rights to the IP from the University of Arizona, will receive $450,000 up front plus $9.5 million over a period of two years from the date of the first approval to begin a Phase II/III trial by a regulatory authority in the U.S. Canada, EU or Thailand. The license includes two products in Phase I/II development to...

Read the full 391 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >